Cargando…
Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review
Ruxolitinib, a Janus kinase inhibitor, improves symptoms in patients with myelofibrosis. However, its association with the development of opportunistic infections has been a concern. We herein report a 71-year-old man with primary myelofibrosis who developed disseminated tuberculosis and concurrent...
Autores principales: | Ogai, Asuka, Yagi, Kazuma, Ito, Fumimaro, Domoto, Hideharu, Shiomi, Tetsuya, Chin, Kenko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107979/ https://www.ncbi.nlm.nih.gov/pubmed/34565769 http://dx.doi.org/10.2169/internalmedicine.6436-20 |
Ejemplares similares
-
Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
por: Hirano, Anna, et al.
Publicado: (2017) -
Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature
por: Tsukamoto, Yasuhiro, et al.
Publicado: (2017) -
FATAL DISSEMINATED CRYPTOCOCCOSIS WITH RENAL INVOLVEMENT IN AN HIV-INFECTED PATIENT
por: DAHER, Elizabeth De Francesco, et al.
Publicado: (2015) -
Disseminated cryptococcosis in an immunocompetent patient
por: Bollam, Rahul, et al.
Publicado: (2020) -
Disseminated Cryptococcosis in an Immunocompetent Child
por: Vijayasekharan, Kalasekhar, et al.
Publicado: (2021)